Voyager Acquisition Secures $29.56M in Secured Notes & Warrants, Establishes $50M ATM Program Amid Liquidity Crisis
Summary
Voyager Acquisition Corp. has secured $29.56 million through a private placement of senior secured notes and warrants, and established a $50 million at-the-market equity program, to address critical liquidity issues and fund its deSPAC transaction.
Key Events
-
Secured Private Placement
PubCo (the post-deSPAC entity) entered into a Securities Purchase Agreement to issue $27.5 million in senior secured notes and warrants to purchase 2,391,305 ordinary shares. The warrants were sold for $2.06 million, with an exercise price of $11.50 per share.
-
At-The-Market (ATM) Program Established
A Purchase Agreement with Lincoln Park Capital Fund, LLC allows PubCo to sell up to $50 million of ordinary shares over 24 months. The purchase price will be 97% of the lower of the lowest daily sale price or the average of the three lowest closing prices during the ten preceding business days.
-
Commitment Shares for ATM Program
As consideration for the ATM program, PubCo will issue $750,000 of ordinary shares to Lincoln Park Capital Fund, LLC.
-
Use of Proceeds & Covenants
Proceeds from the private placement are designated for working capital, general corporate purposes, and up to $500,000 in underwriter compensation. The senior secured notes include strict covenants, such as minimum liquidity and cash burn requirements.
Analysis
This filing details a critical financing package designed to address Voyager Acquisition Corp.'s severe liquidity issues and fund its deSPAC transaction, as highlighted by a recent "going concern" warning. The immediate $29.56 million raised through senior secured notes and warrants, coupled with a $50 million at-the-market equity program, provides a necessary lifeline. However, the terms are highly dilutive for existing shareholders, involving secured debt with strict covenants and a variable-rate ATM program that can exert significant downward pressure on the stock price. The requirement for shareholder approval of charter amendments for future share issuances adds a layer of uncertainty. This is a survival financing, but it comes at a substantial cost.
At the time of this filing, VACH was trading at $9.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $303.9M. The 52-week trading range was $8.40 to $15.68. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.